REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025. “2024 was a momentous year for Adicet as we amplified our efforts in autoimmune diseases and solid tumors. We dosed our first patients in our clinical trials evaluating our gamma delta 1 chimeric a

SAN JOSE, Calif.–(BUSINESS WIRE)–Lawsuit alleges Trumpet Behavioral Health and parent company, BlueSprig, failure to supervise led to the abuse of an autistic child.

ST. LOUIS–(BUSINESS WIRE)–Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board Member to lead Cofactor’s plan to bring precision medicine to immunotherapy. Simultaneously, the company announced that Jarret Glasscock, scientist and Cofactor Genomics founder, will transition into the role of President, Chief Technology Officer (CTO), and Board Member. Parker j

OTTAWA–(BUSINESS WIRE)–In 2024, Ontario’s health care crisis reached new lows: the number of patients in hospital hallways hit a record high; ER closures broke a new threshold; the wait-list for long-term care beds peaked at 48,000, 250,000 people languished on the surgical waitlist and 2.5 million people did not have a family doctor. And yet, advocates say, instead of addressing this crisis the government is needlessly focused on an early election campaign. On Thursday, January 9, Ottawa com

LYON, France–(BUSINESS WIRE)—- $MAAT #Cancer–Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced topline results from ARES, a pivotal, single-arm, open-label, multicenter European Phase 3 study evaluating the efficacy and safety of MaaT013 in acute Graft-versus-Host Disease patients with